MedTrace Logo

Phase I/II Clinical Trial of LBL-015 for Injection

NCT05107011 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-10-28

No results posted yet for this study

Summary

A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-015 in Patients With Advanced Malignant Tumors.

Conditions

  • Advanced Malignant Tumor

Interventions

DRUG

LBL-015 for Injections

Initial dose - MTD ; Q2W ; intravenous infusion

Sponsors & Collaborators

  • Shanghai East Hospital

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Hunan Cancer Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • The First Affiliated Hospital of Bengbu Medical University

    collaborator OTHER

  • Nanjing Leads Biolabs Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Jin li · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-08
Primary Completion
2023-12-05
Completion
2023-12-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05107011 on ClinicalTrials.gov